Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.42 |
| ▸ | PLG | P00747 | 2/20 | 0.41 |
| ▸ | KLK1 | P06870 | 2/20 | 0.41 |
| ▸ | KLK6 | Q92876 | 2/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670564 | 0.85 | ESR1 (0.46) | ESR1ESR2HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL4670203 | 0.82 | ESR1 (0.46) | ESR1ESR2HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL4672161 | 0.81 | ESR1 (0.59) | ESR1ESR2HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL4672262 | 0.81 | PLG (0.46) | ESR1ESR2HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL6588363 | 0.80 | ESR1 (0.47) | ESR1ESR2HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL6588357 | 0.79 | ESR1 (0.46) | ESR1ESR2HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL4672820 | 0.77 | ERN1 (0.46) | ESR1ESR2HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL4672814 | 0.77 | TDO2 (0.37) | F9ROCK1NOS3NOS1 | |
| SCHEMBL7629173 | 0.74 | ALDH1A1 (0.55) | ESR1ESR2HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL4675480 | 0.71 | XDH (0.36) | MEN1KMT2AROCK1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397341-B1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1397341-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6589970-B2 | This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: | WYETH | 2003-07-08 | — | — | US | disclosed |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-03-06 | — | — | US | disclosed |
| WO-2003000649-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | SERPINC1, F11, SERPINE1 | ESR1 2824/4885ESR2 2174/4885HSD17B1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.